NO976122D0 - AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes - Google Patents

AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes

Info

Publication number
NO976122D0
NO976122D0 NO976122A NO976122A NO976122D0 NO 976122 D0 NO976122 D0 NO 976122D0 NO 976122 A NO976122 A NO 976122A NO 976122 A NO976122 A NO 976122A NO 976122 D0 NO976122 D0 NO 976122D0
Authority
NO
Norway
Prior art keywords
antibody
fas ligand
fas
apoptosis
assay method
Prior art date
Application number
NO976122A
Other languages
English (en)
Other versions
NO976122L (no
NO324120B1 (no
Inventor
Kamon Shirakawa
Tomokazu Matsusue
Shigekazu Nagata
Man Sung Co
Maximiliano Vasquez
Original Assignee
Mochida Pharm Co Ltd
Osaka Bioscience Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/649,100 external-priority patent/US6114507A/en
Application filed by Mochida Pharm Co Ltd, Osaka Bioscience Inst filed Critical Mochida Pharm Co Ltd
Publication of NO976122D0 publication Critical patent/NO976122D0/no
Publication of NO976122L publication Critical patent/NO976122L/no
Publication of NO324120B1 publication Critical patent/NO324120B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19976122A 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene. NO324120B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18848095 1995-06-30
US08/649,100 US6114507A (en) 1995-06-30 1996-05-17 Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
PCT/JP1996/001820 WO1997002290A1 (en) 1995-06-30 1996-07-01 ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME

Publications (3)

Publication Number Publication Date
NO976122D0 true NO976122D0 (no) 1997-12-29
NO976122L NO976122L (no) 1998-02-27
NO324120B1 NO324120B1 (no) 2007-08-27

Family

ID=26504954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19976122A NO324120B1 (no) 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene.

Country Status (8)

Country Link
EP (1) EP0842948B1 (no)
JP (1) JP3925663B2 (no)
CN (1) CN1196733A (no)
AU (1) AU724856B2 (no)
CA (1) CA2225852C (no)
NO (1) NO324120B1 (no)
NZ (1) NZ311174A (no)
WO (1) WO1997002290A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010070A1 (en) 1996-09-02 1998-03-12 Sumitomo Electric Industries, Ltd. HUMANIZED IMMUNOGLOBULIN REACTING SPECIFICALLY WITH Fas LIGAND OR ACTIVE FRAGMENTS THEREOF AND REGION INDUCING APOPTOSIS ORIGINATING IN Fas LIGAND
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
US6905684B1 (en) 1997-11-10 2005-06-14 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung diseases
DE69935662D1 (de) 1998-02-06 2007-05-10 Mochida Pharm Co Ltd Mittel zur prävention/behandlung entzündlicher darmerkrankungen
EP1077069B1 (en) * 1998-05-14 2007-05-02 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for hepatic cirrhosis
ATE333287T1 (de) * 1998-05-29 2006-08-15 Mochida Pharm Co Ltd Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4734739B2 (ja) * 2000-09-29 2011-07-27 東レ株式会社 哺乳動物のガン抑制方法
US7262277B2 (en) * 2002-03-21 2007-08-28 Eli Lilly And Company Antagonistic anti-hFAS ligand human antibodies and fragments thereof
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005012363A1 (ja) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. 標的化された炎症惹起剤
DK2101877T3 (da) 2006-12-28 2013-09-23 Deutsches Krebsforsch Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo
ES2538489T3 (es) * 2007-12-12 2015-06-22 Pincell Srl Remedios para pénfigo que contienen anticuerpos contra el ligando Fas
EP2246426A4 (en) 2008-01-29 2011-08-10 Inst Antibodies Co Ltd COMPOSITION FOR THE NEUTRALIZATION OF BOTULINUS TOXIN TYPE-A AND HUMAN ANTIBODIES AGAINST BOTULINUS TOXIN TYPE-A
MX2011006203A (es) 2008-12-12 2011-07-20 Pincell Srl Remedios para penfigo que contienen anticuerpos de ligando antifas.
WO2011010156A1 (en) * 2009-07-21 2011-01-27 Queen Mary & Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
JO3437B1 (ar) * 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
CN106415269B (zh) * 2014-05-08 2020-11-27 贵州美鑫达医疗科技有限公司 直接免疫组织化学测定
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
JP6884785B2 (ja) * 2015-09-23 2021-06-09 アポジェニックス アーゲー 抗ｃｄ９５ｌ抗体
SMT202300437T1 (it) * 2017-03-10 2024-01-10 University Of Louisville Research Foundation Inc Biomateriali ingegnerizzati con fasl con funzione immunomodulatoria
CN116888257A (zh) * 2022-01-21 2023-10-13 北京三诺佳邑生物技术有限责任公司 特异性识别FasL的抗体及其应用
CN119095621A (zh) 2022-04-26 2024-12-06 弗哈夫曼拉罗切有限公司 用于治疗癌症的包括Fas轴拮抗剂和T-reg细胞消耗剂拮抗剂的联合疗法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
EP0723556A4 (en) 1993-10-14 2003-03-19 Immunex Corp FAS ANTAGONISTS AND THEIR APPLICATIONS
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
NZ279108A (en) * 1994-01-07 1997-06-24 Immunex Corp Human fas (tgf/ngf receptor) ligand proteins coding sequences and production
AU716731B2 (en) * 1995-03-20 2000-03-02 Ko Okumura Monoclonal antibody reacting specifically with Fas ligand and process for producing the same

Also Published As

Publication number Publication date
WO1997002290A1 (en) 1997-01-23
CN1196733A (zh) 1998-10-21
NO976122L (no) 1998-02-27
JP3925663B2 (ja) 2007-06-06
AU724856B2 (en) 2000-10-05
CA2225852A1 (en) 1997-01-23
NZ311174A (en) 1999-04-29
CA2225852C (en) 2009-04-14
AU6243596A (en) 1997-02-05
EP0842948B1 (en) 2009-04-22
EP0842948A4 (en) 2004-12-15
NO324120B1 (no) 2007-08-27
EP0842948A1 (en) 1998-05-20

Similar Documents

Publication Publication Date Title
CA2225852A1 (en) Anti-fas ligand antibody and assay method using the anti-fas ligand antibody
Plotz et al. Assignment of direct and facilitated hemolytic plaques in mice to specific immunoglobulin classes
Schuurman et al. Normal human immunoglobulin G4 is bispecific: it has two different antigen‐combining sites
DE69322860D1 (de) Antikörper gegen alpha v beta 3 integrin
CA2105644A1 (en) Resurfacing of rodent antibodies
DE69637909D1 (de) ANTI-Fas-LIGAND ANTIKÖRPER UND TESTMETHODE UNTER VERWENDUNG DERSELBEN
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
Lesley et al. Antigen receptor molecules: inhibition by antiserum against kappa light chains
NO965239L (no) Monoklonalt antistoff mot CD44v6
DK0552296T3 (da) Monoklonale antistoffer fra mus
JP7835815B2 (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
KR960010024A (ko) 류머티즘 치료제
SE8300320D0 (sv) Monoclonal antibody formulation for diagnostic use
DE69431526T2 (de) Ligand fähig zur bindung an der adenosinedeaminase-bindungsstelle von cd26
Sulica et al. Effect of protein A of Staphylococcus aureus on the binding of monomeric and polymeric IgG to Fc receptor-bearing cells
Martens et al. Increased circulating interleukin‐6 (IL‐6) activity in endotoxin‐challenged mice pretreated with anti‐IL‐6 antibody is due to IL‐6 accumulated in antigen‐antibody complexes
Cline et al. Immunoglobulin receptors on a mouse mast cell tumor
ID25978A (id) Antibodi anti-fas
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
Yu et al. A monoclonal antibody with anti‐D–like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
DE69018968D1 (de) BLUTGERINNUNGSFAKTOR BETA XIIa MONOKLONALE ANTIKÖRPER UND IMMUNANALYSE.
Ezzatifar et al. Large scale generation and characterization of anti-human IgA monoclonal antibody in ascitic fluid of BALB/c mice
BG96346A (bg) Специфични свързващи вещества